- Citations, last 5 years
- 3
- Works, last 5 years
- 4
- h-index
- 7
- Scientists listed
- 1
- Grants since 2016
- 6
Grants received
2018–2024 · research · R01
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)
Leonide Saad · Alkeus Pharmaceuticals (United States) · funded by U.S. Food and Drug Administration
2018–2022 · research · R01
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)
Leonide Saad · Alkeus Pharmaceuticals (United States) · funded by U.S. Food and Drug Administration
2018–2025 · research · R01
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)
Leonide Saad · Alkeus Pharmaceuticals (United States) · funded by U.S. Food and Drug Administration
2018–2023 · research · R01
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)
Leonide Saad · Alkeus Pharmaceuticals (United States) · funded by U.S. Food and Drug Administration
2017–2018 · research · R01
ALK-001 Phase 2 Treatment of Stargardt Disease IND 108,353 (09/08/2015)
Leonide Saad · Alkeus Pharmaceuticals (United States) · funded by U.S. Food and Drug Administration
2012–2022 · research · R44
A Phase 2a clinical trial of ALK-001 in geographic atrophy
Leonide Saad · Alkeus Pharmaceuticals (United States) · funded by National Institutes of Health
